Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438545 | 0.91 | FFAR1 (0.48) | FFAR1AKR1B1OXTRAVPR1APTPN1 | |
| SCHEMBL2700 | 0.90 | AGTR1 (0.47) | FFAR1AKR1B1OXTRAVPR1APTPN1 | |
| SCHEMBL2034 | 0.90 | AGTR1 (0.47) | FFAR1AKR1B1OXTRAVPR1APTPN1 | |
| SCHEMBL2443439 | 0.89 | LTB4R2 (0.44) | FFAR1AKR1B1OXTRAVPR1APTPN1 | |
| SCHEMBL2780 | 0.87 | FFAR1 (0.35) | FFAR1AKR1B1OXTRAVPR1APTPN1 | |
| SCHEMBL1809623 | 0.85 | AGTR1 (0.54) | FFAR1AKR1B1LTB4R2AGTR1ABCB11 | |
| SCHEMBL29378073 | 0.85 | AGTR1 (0.54) | FFAR1AKR1B1LTB4R2AGTR1ABCB11 | |
| SCHEMBL2140 | 0.85 | AGTR1 (0.54) | FFAR1AKR1B1LTB4R2AGTR1ABCB11 | |
| SCHEMBL2989 | 0.84 | FFAR1 (0.43) | FFAR1AKR1B1OXTRAVPR1APTPN1 | |
| SCHEMBL2980 | 0.83 | AGTR1 (0.42) | FFAR1AKR1B1OXTRAVPR1APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492577-B2 | Process for preparation of valsartan intermediate | HETERO RESEARCH FOUNDATION (IN) | 2013-07-23 | — | — | US | disclosed |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-29 | — | — | US | disclosed |
| EP-2260018-A2 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010133909-A2 | PROCESS FOR PREPARATION OF 5-SUBSTITUTED TETRAZOLES | SMS PHARMACEUTICALS LIMITED (IN) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009125416-A2 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2009-10-15 | — | — | WO | disclosed |
| US-7361770-B2 | Process for preparation of valsartan | HETERO DRUGS LIMITED (IN) | 2008-04-22 | — | — | US | disclosed |
| US-20060100443-A1 | Novel process for preparation of valsartan | HETERO DRUGS LIMITED (IN) | 2006-05-11 | — | — | US | disclosed |
| WO-2005049588-A1 | PROCESS FOR ISOLATION OF VALSARTAN | RANBAXY LABORATORIES LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004111018-A1 | A NOVEL PROCESS FOR PREPARATION OF VALSARTAN | HETERO DRUGS LIMITED (IN) | 2004-12-23 | — | — | WO | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | REN, AGT, ACE | FFAR1 2643/4885AKR1B1 139/4885OXTR 1774/4885 |
| US-20060100443-A1 | Novel process for preparation of valsartan | ACE, REN, AGT | FFAR1 1526/4885AKR1B1 369/4885OXTR 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.